AQB is a micro-cap land-based aquaculture company best known for developing AquAdvantage, a genetically engineered Atlantic salmon. After years of losses and cost overruns, it shut down its Indiana farm, paused the unfinished Ohio Farm Project, and shifted to selling assets and pursuing strategic alternatives. That restructuring has left the stock essentially without analyst coverage: TipRanks lists zero analysts with a 12-month price target, and the last substantive ratings — including a "Neutral" from H.C. Wainwright and "Market Perform" from Oppenheimer in 2024 — predate the wind-down. A single stale $1.00 target dated November 2024 remains in some databases, but it is not a usable, current consensus.
Because no credible aggregate analyst price target exists, the $1.50 figure used here is a fallback objective grounded in public technical discussion rather than a published consensus. It sits meaningfully above the $1.00 Nasdaq minimum-bid threshold the company was required to clear, and it lies within the stock's 52-week trading range, which has reached roughly $2.95. It should be read as a speculative, recovery-scenario milestone — not a forecast any analyst has formally published. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Shares have traded near $0.95, leaving the company with a market value of only a few million dollars. Reaching $1.50 would require approximately 58% appreciation, which is best described as a very large move for any security, even this highly volatile one. The path would depend less on fundamentals than on two catalysts: securing financing and completing a value-creating transaction for the Ohio property. In 2026 management expanded its strategic review to include power generation, digital infrastructure, and energy development uses for the Pioneer, Ohio site — a significant departure from aquaculture. Any credible monetization of that real estate, or a new capital injection, could support a sharp repricing, while continued inaction would likely pressure the shares.
The $1.00 level functions as both a psychological mark and a regulatory compliance threshold, making it a key area to watch; sustained trading below it would refocus attention on listing risk. Above that, $1.50 represents the next round-number resistance zone used here as the target. The 52-week high near $2.95 marks the upper bound of recent trading, while support has formed near the $0.70–$0.77 lows. With very thin average volume and a micro-cap float, technical levels are especially fragile and prone to gap moves. From what I see, the volatility patterns here are worth monitoring closely with automated tools.
Because no formal analyst target exists, there is no standard 12-month research horizon to reference; the $1.50 level is a milestone rather than a dated forecast. Investors should monitor the company's quarterly filings and cash balance, any update on the Ohio strategic review and potential energy or infrastructure transaction, further preferred or equity financing and its dilution, and Nasdaq listing-status developments, including the proposed market-value rule. Earnings releases and 8-K filings remain the primary sources of material news for a company with minimal sell-side coverage.
In my view, Tickeron's AI Daily Buy/Sell Signals offer a practical way to stay on top of names like AQB. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a volatile, low-liquidity name such as AQB, automated monitoring can help traders spot changing trends, manage open positions, and surface opportunities more efficiently than manual review. Traders can use the tool to complement their own research and stay alert to momentum shifts across the broader market. I find it especially helpful when reviewing technical setups for micro-cap names where liquidity is thin.
Can AQB reach $1.50? The target is not an analyst-derived consensus but a speculative technical milestone roughly 58% above the recent price. A move of that size is conceivable given the stock's extreme volatility, but it would almost certainly require a transformative event — a monetization of the Ohio property or a substantial capital injection — rather than an improvement in operating fundamentals, because the company's legacy salmon business has been largely wound down. Against that, investors must weigh the going-concern warning, a thin cash position, dilutive financing, and genuine delisting risk. The balance of evidence is cautious, and the outcome will depend on corporate actions and financing rather than earnings. No price target or forecast should be treated as a guarantee.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AQB saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 05, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 41 instances where the indicator turned negative. In 38 of the 41 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AQB as a result. In 82 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
AQB moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AQB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
AQB broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AQB's RSI Oscillator exited the oversold zone, 36 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for AQB crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 89%.
Following a +8.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where AQB advanced for three days, in 155 of 207 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 64 of 85 cases where AQB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.793) is normal, around the industry mean (2.266). P/E Ratio (-0.214) is within average values for comparable stocks, (4.366). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.441). AQB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (2.089) is also within normal values, averaging (2.353).
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. AQB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AQB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a biotechnology company focused on improving productivity in commercial aquaculture
Industry AgriculturalCommoditiesMilling